Tarsus Pharmaceuticals Inc (TARS) — Capital Reinvestment Ratio

Latest as of December 2025: 0.33x

Tarsus Pharmaceuticals Inc (TARS) has a Capital Reinvestment Ratio of 0.33x as of December 2025, meaning it reinvests 0% of its operating cash flow ($19.33 Million) in capital expenditures ($6.36 Million). See debt-free asset ratio of Tarsus Pharmaceuticals Inc to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.33x
Capex / Operating Cash Flow

Operating Cash Flow

$19.33 Million
USD

Capital Expenditures

$6.36 Million
USD

Data as of

Dec 2025
Most recent filing

Tarsus Pharmaceuticals Inc Capital Reinvestment Ratio (2021–2021)

This chart tracks Tarsus Pharmaceuticals Inc's Capital Reinvestment Ratio across 1 annual periods. Check Tarsus Pharmaceuticals Inc (TARS) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Tarsus Pharmaceuticals Inc (2021–2021)

Year-by-year Capital Reinvestment Ratio for Tarsus Pharmaceuticals Inc from 2021 to 2021. For live market cap and broader valuation context, see Tarsus Pharmaceuticals Inc (TARS) market capitalisation.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2021 0.16x $3.75 Million $586.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow